SCHEMBL800632

SCHEMBL800632

COC(=O)c1ccc(CNC(=O)CCCCOC2CCCn3c2nc(C)c(CCN2CCC(c4noc5cc(F)ccc45)CC2)c3=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 14/20 0.61
DRD2 P14416 13/20 0.61
DRD3 P35462 4/20 0.61
ADRA2A P08913 3/20 0.61
ADRA2B P18089 3/20 0.61
ADRA2C P18825 3/20 0.61
DRD1 P21728 3/20 0.61
DRD4 P21917 3/20 0.61
HTR2C P28335 3/20 0.61
ADRA1A P35348 3/20 0.61
HRH1 P35367 3/20 0.61
KCNH2 Q12809 3/20 0.61
DRD5 P21918 2/20 0.61
HTR1D P28221 2/20 0.61
HTR1B P28222 2/20 0.61
HTR7 P34969 2/20 0.61
SCN5A Q14524 2/20 0.61
KCND3 Q9UK17 1/20 0.61
HTR1A P08908 4/20 0.56
CHRM2 P08172 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801116 0.95 DRD2 (0.62) HTR2ADRD2DRD3ADRA2AADRA2B
SCHEMBL12295327 0.95 DRD2 (0.62) HTR2ADRD2DRD3ADRA2AADRA2B
SCHEMBL800896 0.95 HTR2A (0.59) HTR2ADRD2DRD3ADRA2AADRA2B
SCHEMBL801110 0.90 DRD2 (0.53) HTR2ADRD2DRD3ADRA2AADRA2B
SCHEMBL12295328 0.89 DRD2 (0.52) HTR2ADRD2DRD3ADRA2AADRA2B
SCHEMBL19795390 0.88 HTR2A (0.68) HTR2ADRD2DRD3ADRA2AADRA2B
SCHEMBL801029 0.88 HTR2A (0.70) HTR2ADRD2DRD3ADRA2AADRA2B
SCHEMBL801035 0.87 DRD2 (0.72) HTR2ADRD2DRD3ADRA2AADRA2B
SCHEMBL800566 0.87 DRD2 (0.72) HTR2ADRD2DRD3ADRA2AADRA2B
SCHEMBL15485630 0.86 DRD2 (0.71) HTR2ADRD2DRD3ADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130245241-A1 Risperidone Immunoassay SALADAX BIOMEDICAL INC. (US) 2013-09-19 US disclosed
US-8450461-B2 Risperidone immunoassay SALADAX BIOMEDICAL INC. (US) 2013-05-28 US disclosed
US-20120071636-A1 RISPERIDONE IMMUNOASSAY SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) 2012-03-22 US disclosed
US-8088594-B2 Risperidone immunoassay SALADAX BIOMEDICAL INC. (US) 2012-01-03 US disclosed
US-20110229979-A1 RISPERIDONE IMMUNOASSAY SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110229979-A1 RISPERIDONE IMMUNOASSAY PRLHR, PA2G4, PRSS12 HTR2A 93/4885DRD2 26/4885DRD3 20/4885
US-20120071636-A1 RISPERIDONE IMMUNOASSAY PRLHR, PA2G4, PRSS12 HTR2A 93/4885DRD2 26/4885DRD3 20/4885
US-20130245241-A1 Risperidone Immunoassay PRLHR, PA2G4, PRSS12 HTR2A 93/4885DRD2 26/4885DRD3 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.